Researchers at the German Cancer Research Center (DKFZ) have succeeded in identifying a resistance mechanism that often occurs in a specific targeted therapy against chronic lymphocytic leukemia (CLL). The drug ibrutinib is effective in many cases, but therapy resistance often develops during the course of treatment. In cell culture experiments and in mice, the resistance mechanism was successfully overcome using a second drug.

Using artificial intelligence to revolutionize drug development is the aim of the start-up "EmbryoNet AI Technologies" led by Konstanz biologist Patrick Müller. Müller and his team have now been awarded the start-up prize by the Federal Ministry for Economic Affairs and Climate Action (BMWK) for their business concept.

SpecPlate: an innovative multiwell plate - 26/03/2025

Focus on innovative drug development - accurate, time- and cost-saving

Drug research is a complex and costly process that requires extensive laboratory analyses and vast quantities of consumables, with disposable sample carriers in particular being used in their millions. PHABIOC GmbH has come up with a solution in the form of the SpecPlate, a ground-breaking alternative to sample carriers that reduces the time taken to perform analyses as well as the quantity of materials consumed. Serial production is underway.

Microorganisms produce nutrients in bioreactors - 12/03/2025

CO2 and H2 as starting materials for proteins and vitamins

Agricultural land needed to sustain the world's growing population is becoming increasingly scarce. To help address this challenge, researchers from the Environmental Biotechnology Group at the University of Tübingen have developed an innovative and sustainable power-to-vitamin technology. This breakthrough enables protein- and vitamin-rich foods to be produced with the help of microorganisms in a bioreactor using carbon dioxide and…

A recent article by Prof. Dr. Martin Haimerl and Prof. Dr. Christoph Reich of Furtwangen University shows that machine learning (ML) in medicine is often evaluated without a comprehensive risk assessment. The authors investigated the extent to which current scientific papers include risk-based metrics in the evaluation of AI models for medical devices.

Two molecular control factors play a decisive role in what is known as splicing, the cutting and assembly of mature messenger RNA – a prerequisite for protein synthesis in the cell. The poorly characterized factors are crucial to ensuring that the molecular machine responsible for splicing is working correctly. A research team has deciphered how the two cellular quality inspectors work.

84 percent of Germans consciously consider their diet. For the majority, nutrition is a central topic, but many perceive the public debate as divisive and patronising. According to the latest nutrition study by the Robert Bosch Stiftung and the More in Common, citizens want policies that promote healthy, regional, and affordable food – without regulations or bans. At the same time, they are calling for more say in shaping the food system.

The ‘Photon-Counting’ (PC) - CT consortium is entering the next round of funding from the Forum Health Region Baden-Württemberg. The new consortium will install the image data infrastructure ‘teamplay digital health platform connect’ (tdhp) at four clinical sites in the follow-up project PC3-AIDA.

Die BIOPRO Baden-Württemberg begleitet in den Jahren 2021 und 2022 die Gründung des "Baden-Württemberg-Center for Academic Drug Discovery" (BWCAD2).

Installing the next digital generation of computed tomography at various Baden-Württemberg medical centres (PC3)

Baden-Württemberg AI Alliance - 08/04/2025

Achieving widespread use of AI

Artificial intelligence presents both opportunities and risks. The Baden-Württemberg AI Alliance is dedicated to fostering collaboration among AI stakeholders to ensure that AI solutions deliver tangible benefits to citizens and businesses across the state. The alliance will also place greater emphasis on advancing AI applications within the healthcare sector.

Researchers from the universities in Konstanz and Vienna discover a new class of antibiotic that selectively targets Neisseria gonorrhoeae, the bacterium that causes gonorrhoea. These substances trigger a self-destruction program, which also operates in multi-resistant variants of the pathogen. The novel findings are published in the current issue of Nature Microbiology.